ライフサイエンスコーパス: topoisomerase II

1 nd the enrichment of cohesin, condensin, and topoisomerase II.

2 on decatenated DNA, it is rapidly relaxed by topoisomerase II.

3 lso accumulates during RNAi of mitochondrial topoisomerase II.

4 al chromatid axes labeled with antibodies to topoisomerase II.

5 ar processes outside of its activity against topoisomerase II.

6 pyrones A-D also act as poisons of human DNA topoisomerase II.

7 of fluorescence anisotropy with intact human topoisomerase II.

8 and (c) no inhibitory activity against human topoisomerase II.

9 antibacterial ciprofloxacin can poison yeast topoisomerase II.

10 supercoiling is more efficiently removed by topoisomerase II.

11 novel mechanism involving TRIM28, DNA-PK and topoisomerase II.

12 Topoisomerase-II accumulates at centromeres during prome

13 , processes which govern centromere-specific topoisomerase-II accumulation/activation have been funct

14 Further, doxazolidine has little effect in a topoisomerase II activity assay.

15 ce to anaphase, suggesting the importance of topoisomerase II activity for proper chromosome condensa

16 icated that XWL-1-48 significantly inhibited topoisomerase II activity in a concentration-dependent m

17 tivity, implicating transcription as well as topoisomerase II activity in the translocation mechanism

18 percoiling takes place in catenated plasmid, topoisomerase II activity is directed toward decatenatio

19 eorganization is marked by specific sites of topoisomerase II activity that are initially detected in

20 The inhibition of topoisomerase II activity using specific inhibitors reve

21 nly used chemotherapeutic drug that inhibits topoisomerase II activity, thereby leading to genotoxici

22 osome architecture in a manner that involves topoisomerase II activity.

23 We find that topoisomerase-II activity is concentrated at single chro

24 as the result of a mutation in the zebrafish topoisomerase II alpha (top2a) gene.

25 protein 4 (CBX4) transcriptionally activates Topoisomerase II alpha (TOP2alpha).

26 nzodiazepine-polypyrrole compounds and human Topoisomerase II alpha promoter DNA.

27 Topoisomerase II alpha, which is highly conserved among

28 ore, EMI1-depleted mammalian cells relied on topoisomerase II alpha-dependent mitotic decatenation to

29 d breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme t

30 Topoisomerase-II-alpha (TOPO-II-alpha), which is associa

31 ement for the phosphoryltransfer reaction of topoisomerase II and a possible mechanism for drug resis

32 and coordinates the two protomer subunits of topoisomerase II and allows the enzyme to create double-

33 SUMOylation (of topoisomerase II and axis component Red1) and ubiquitin-

34 We have identified previously topoisomerase II and heat shock protein 90 (Hsp90) as pa

35 hat Escherichia coli topoisomerase IV, yeast topoisomerase II and human topoisomerase IIalpha each be

36 roups on etoposide that associate with yeast topoisomerase II and human topoisomerase IIalpha.

37 iosmerase II activity but not degradation of topoisomerase II and it is this, in the presence of a to

38 r with the DNA cleavage/ligation reaction of topoisomerase II and other aspects of its catalytic cycl

39 uman RecQ family of helicases interacts with Topoisomerase II and plays a role in chromosome segregat

40 Etoposide is known to bind to topoisomerase II and prevent the resolution of the "clea

41 larubicin, which is a catalytic inhibitor of topoisomerase II and prevents the formation of the cleav

42 which traps a cleavage intermediate between topoisomerase II and torsionally strained DNA.

43 At late prophase, dependent on topoisomerase II and with concomitant cohesin release, c

44 ant requirement for intertwine resolution by topoisomerase II and, together with the inhibition of tr

45 These breaks were reliant on topoisomerase II, and BRD2 directly bound and activated

46 ion is reduced by inhibition or depletion of topoisomerase II, and this is accompanied by reduced tra

47 Anthracyclines interact with DNA and topoisomerase II as well as with cell membranes, and it

48 The enzyme DNA topoisomerase II associates with gene promoter regions a

49 ty to 12% of the tested compounds, including topoisomerase II, B-cell chronic lymphocytic leukemia/ly

50 l elongation-coupled DDR signalling involves topoisomerase II because inhibiting this enzyme interfer

51 Topoisomerase II beta (TOP2B) facilitates rapid gene exp

52 otes co-recruitment of androgen receptor and topoisomerase II beta (TOP2B) to sites of TMPRSS2-ERG ge

53 d by new insights that anthracycline targets topoisomerase II beta to cause DNA double-strand breaks

54 s should be based on inhibiting or degrading topoisomerase II beta.

55 tinostat and doxorubicin treatment inhibited topoisomerase II-beta (TopoII-beta) and relieved TopoII-

56 lude that the drug-DNA complex formed blocks topoisomerase II binding and activity leading to catalyt

57 hat the damage sensor ATR in the presence of topoisomerase II binding protein 1 (TopBP1) mediator/ada

58 ring together with Treslin/TICRR and TopBP1 (Topoisomerase II binding protein 1 (TopBP1)-interacting

59 ETAA1 activator of ATR kinase (ETAA1) or DNA topoisomerase II binding protein 1 (TOPBP1).

60 Competition DNA cleavage and topoisomerase II binding studies indicate that the 5-OH

61 s and found that NONO favours the loading of topoisomerase II-binding protein 1 acting upstream of th

62 N-terminal and central domains of eukaryotic topoisomerase II but naturally lack the C-terminal domai

63 hich merbarone, a catalytic inhibitor of DNA topoisomerase II, can block tumor cell growth without in

64 Consequently, topoisomerase II cannot efficiently ligate phosphorothio

65 henotypes are similar to those observed when Topoisomerase II catalytic activity is inhibited.

66 the presence of ATP, similar to the overall topoisomerase II catalyzed reaction.

67 agments from the nuclear matrix by promoting topoisomerase II-catalyzed DNA cleavage, because the dru

68 rt and extend current mechanistic models for topoisomerase II-catalyzed DNA transport and provide a f

69 Topoisomerase II catalyzes the ATP-dependent transport o

70 Topoisomerase II causes transient double-strand breaks i

71 e it plays a critical role for the repair of topoisomerase II cleavage complexes (Top2cc) and encodes

72 Etoposide metabolites induced topoisomerase II cleavage complexes that could form both

73 These results are consistent with repair of topoisomerase II cleavage from etoposide metabolites as

74 n located within the four-base overhang of a topoisomerase II cleavage site (at the +2 or +3 position

75 e with a pair of fluorophores straddling the topoisomerase II cleavage site, allowing the use of FRET

76 Defined topoisomerase II cleavage sites in genomic and plasmid D

77 this issue, we have used etoposide-mediated topoisomerase-II cleavage as a biochemical marker to map

78 A shared feature of these topoisomerase-II cleavage sites is the presence of an ex

79 sing approaches including etoposide-mediated topoisomerase-II cleavage, we mapped centromeric domains

80 along a single, peripheral, regularly kinked topoisomerase II/cohesin/condensin II axis.

81 DNA topoisomerase II completely removes DNA intertwining, or

82 eavage data suggest factors other than local topoisomerase II concentration determine specific cluste

83 nd cleavage core of Saccharomyces cerevisiae topoisomerase II covalently linked to DNA through its ac

84 dine growth inhibition of HL-60/MX2 cells, a topoisomerase II deficient derivative of HL-60 cells, is

85 A recent study that focused on yeast topoisomerase II demonstrated that the H15 geminal proto

86 -60 leukemia cells through a well-documented topoisomerase II dependent mechanism.

87 ing resistance to poisons of human and yeast topoisomerase II derive from a rich mutational 'landscap

88 1 and TOP2, respectively) poisons as well as topoisomerase II DNA binding and ATPase inhibitors signi

89 e for future studies on DNA scission and the topoisomerase II-DNA cleavage complex.

90 ral products that bind to DNA and poison the topoisomerase II-DNA complex in cancer cells.

91 he first 'open clamp' structures of a 3-gate topoisomerase II-DNA complex, the seminal complex engage

92 ent to proliferating cell nuclear antigen or topoisomerase II does not affect doxorubicin cytotoxicit

93 in C, a bifunctional alkylator, etoposide, a topoisomerase II drug, and UV light, but not ionizing ra

94 ons, mediate the entry of etoposide into the topoisomerase II-drug-DNA complex, the substituents on e

95 pattern indicates the active requirement of topoisomerase II during these stages of the cell cycle.

96 llowing genotoxic and replication stress, or topoisomerase II dysfunction, and these mitotic defects

97 ch as DNA polymerase, RNA polymerase II, and topoisomerase II eliminated micron-scale coherence, whil

98 osphosites evolved from acidic residues (DNA topoisomerase II, enolase, and C-Raf) show that the rele

99 ng bacterial topoisomerase IV and eukaryotic topoisomerase II enzymes, can carry out both intra- and

100 KEY MESSAGE: The topoisomerase II expression varies as a function of cell

101 Maximal topoisomerase II expression was tightly coupled to S pha

102 in-depth analysis of energy transduction by topoisomerase II, for guiding and interpreting future st

103 a partial gene duplication of the C. elegans topoisomerase II gene, top-2.

104 sms by which these agents increase levels of topoisomerase II-generated DNA strand breaks.

105 ry out its critical physiological functions, topoisomerase II generates transient double-stranded bre

106 The variable carboxyl terminal region of topoisomerase-II has a major role in regulating biologic

107 Topoisomerase-II has been identified as a crucial regula

108 In other organisms, sumoylation of topoisomerase-II has been shown to be necessary for regu

109 ids against the individual isoforms of human topoisomerase II have not been analyzed.

110 omerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities agains

111 on the enzymatic activities of condensin and topoisomerase II in overwinding and relaxation of the DN

112 tact between these portions of etoposide and topoisomerase II in the binary complex.

113 nd 5'-methoxyl protons of the E-ring contact topoisomerase II in the binary enzyme-drug complex.

114 d DNA gate, we could monitor the movement of topoisomerase II in the presence of cofactors and detect

115 cell cultures were used to study the role of topoisomerase II in various stages of the cell cycle.

116 n of TbPIF1 is an involvement, together with topoisomerase II, in the segregation of minicircle proge

117 mechanisms and doxazolidine cytotoxicity is topoisomerase II independent.

118 increased susceptibility and sensitivity to topoisomerase-II-induced DNA double-strand breaks.

119 Its primary mode of action appears to be topoisomerase II inhibition, DNA cleavage, and free radi

120 for the adaptive response that bypasses the topoisomerase II inhibition----mediated G(2) arrest.

121 ial type II topoisomerases mediated by human topoisomerase II inhibition.

122 cin is a synthetic anthracycline with potent topoisomerase II inhibition.

123 Mice were treated with vehicle, M3814 alone, topoisomerase II inhibitor alone, and M3814 in combinati

124 hylamino N-oxide groups, is converted to the topoisomerase II inhibitor AQ4 [1,4-bis{[2-(dimethylamin

125 avage induced by a lower dose (5 muM) of the topoisomerase II inhibitor etoposide.

126 Thus, XWL-1-48 may be a promising orally topoisomerase II inhibitor for treatment of HCC.

127 ation could be prevented by treatment with a topoisomerase II inhibitor ICRF-193, suggesting that the

128 th topoisomerase I poison trials, ifosfamide/topoisomerase II inhibitor trials had superior FFS (P =

129 DRZ is a topoisomerase II inhibitor with a mechanism distinct fro

130 ases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing

131 hibitor alone, and M3814 in combination with topoisomerase II inhibitor, and change in tumor volume o

132 toposide, a widely used antitumor drug and a topoisomerase II inhibitor, is a prototypical inducer of

133 a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in

134 showing that DJ34 is a DNA intercalator and topoisomerase II inhibitor.

135 vative, XWL-1-48, was synthesized as an oral topoisomerase II inhibitor.

136 h this property, treatment of cells with the topoisomerase-II inhibitor etoposide promotes chromosoma

137 , and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methot

138 zed with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemot

139 ificantly enhances cell death induced by the topoisomerase II inhibitors etoposide and doxorubicin an

140 e cellular ultrastructure that differed from topoisomerase II inhibitors including induction of spher

141 706744) and NSC 724998, but sensitive to the topoisomerase II inhibitors mitoxantrone and etoposide.

142 cancer therapy with radiation, platinum and topoisomerase II inhibitors preferentially selects for m

143 y twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal

144 tivity of M3814 in combination with multiple topoisomerase II inhibitors, doxorubicin, etoposide, and

145 Diverse pro-apoptotic drugs, including topoisomerase II inhibitors, kinase inhibitors, and prot

146 e specifically to mitoxantrone, not to other topoisomerase II inhibitors.

147 thesized dual-acting histone deacetylase and topoisomerase II inhibitors.

148 -damaging agents, including radiotherapy and topoisomerase II inhibitors.

149 e the inhibition of Hsp90 disrupts the Hsp90-topoisomerase II interaction leading to an increase in a

150 DNA topoisomerase II is a molecular machine that couples ATP

151 Topoisomerase II is an essential enzyme that is required

152 Human DNA topoisomerase II is an important target in anticancer th

153 ual-target or multiple-target inhibitors, as topoisomerase II is both structurally (e.g., topoisomera

154 Contrary, topoisomerase II is not the major component of meiotic c

155 somes treated with these compounds; however, topoisomerase II is probably not the main drug target.

156 Even if topoisomerase II is required for individualization and c

157 seen after fixation of cells, we found that topoisomerase II is required for linear condensation.

158 DNA decatenation mediated by Topoisomerase II is required to separate the interlinked

159 Topoisomerase II is similarly required for linear chromo

160 he immuno-staining analysis also showed that topoisomerase II is the major component of mitotic chrom

161 The DNA cleavage/ligation reaction of topoisomerase II is the target for some of the most succ

162 ely used chemotherapeutic drug that inhibits topoisomerase II, is the mainstay of treatment for HLH,

163 f CIN-4, suggesting that CIN-4 and TOP-2 are topoisomerase II isoforms that perform separate essentia

164 Both human Topoisomerase II isoforms, alpha and beta, are targeted

165 duced drug-induced DNA damage and diminished topoisomerase II levels and activity; however, mechanism

166 and activity; however, mechanisms regulating topoisomerase II levels differed depending on culture co

167 formed by Spo11 (Rec12 in fission yeast), a topoisomerase II-like protein, which becomes covalently

168 r-specific DSBs induced by etoposide are not topoisomerase II-linked but the result of apoptotic nucl

169 Neoamphimedine can efficiently induce topoisomerase II mediated catenation of plasmid DNA in v

170 ing and the mechanism behind the increase in topoisomerase II mediated DNA damage.

171 zed DNA cleavage, because the drug inhibited topoisomerase II-mediated cleavage in isolated nuclear m

172 ance of E-ring substituents was confirmed by topoisomerase II-mediated DNA cleavage assays.

173 se II poisons (i.e., they increase levels of topoisomerase II-mediated DNA cleavage).

174 idation, the dietary spice turmeric enhanced topoisomerase II-mediated DNA cleavage.

175 d display an abnormal cell cycle response to topoisomerase II-mediated DNA damage.

176 toposide and amsacrine that strongly inhibit topoisomerase II-mediated DNA ligation have little effec

177 erefore, to establish a system that isolates topoisomerase II-mediated DNA scission from ligation, ol

178 prescribed anticancer agent that stabilizes topoisomerase II-mediated DNA strand breaks.

179 Topoisomerase II modulates DNA topology by generating do

180 DNA topoisomerase II modulates DNA topology by relieving sup

181 ynthetic lethality of smc6 hypomorphs with a topoisomerase II mutant, defective in mitotic chromosome

182 wo IIV-3 genes, including those encoding DNA topoisomerase II, NAD-dependent DNA ligase, SF1 helicase

183 ruplex ligand pyridostatin involves trapping topoisomerase II on DNA.

184 we express full-length Plasmodium falciparum topoisomerase II (PfTopoII) in a wheat germ cell-free tr

185 Topoisomerase II plays a central role, thus identifying

186 Topoisomerase II plays a crucial role during chromosome

187 viral enzyme and imply that chlorella virus topoisomerase II plays a physiological role beyond the c

188 r inter-sister homologous recombination, and topoisomerase II plays a role in generating the damage.

189 is studies suggest that the TOPRIM region of topoisomerase II plays a role in genistein binding.

190 a cells confers collateral resistance to the topoisomerase II poison doxorubicin.

191 opoisomerase II, which, in the presence of a topoisomerase II poison leads to the formation of an inc

192 rase II and it is this, in the presence of a topoisomerase II poison that causes the increase in cell

193 Etoposide is a topoisomerase II poison that is used to treat a variety

194 e, and change the mechanism of action from a topoisomerase II poison to a DNA cross-linker.

195 tumors displayed an enhanced response to the topoisomerase-II poison etoposide.

196 xerts its primary cytotoxic activity through topoisomerase II poisoning.

197 can form quinones have been shown to act as topoisomerase II poisons (i.e., they increase levels of

198 ponse of cancer patients to the broadly used topoisomerase II poisons and defines alternative pathway

199 Topoisomerase II poisons are one of the most common clas

200 are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agen

201 The topoisomerase II poisons doxorubicin and etoposide const

202 he hypothesis that bioflavonoids function as topoisomerase II poisons in humans and provide a framewo

203 The effects of these topoisomerase II poisons may result as mortalin-based cy

204 Thus, nicks are topoisomerase II poisons that generate novel sites of DN

205 17 months after starting treatment following topoisomerase II poisons, alkylating agents, local radia

206 redox-dependent (as opposed to interfacial) topoisomerase II poisons.

207 curcumin intermediates appear to function as topoisomerase II poisons.

208 erase IIalpha and the mechanism of action of topoisomerase II poisons.

209 ibed anticancer drug, are well-characterized topoisomerase II poisons.

210 cts have been attributed to their actions as topoisomerase II poisons.

211 ir role in the actions of these compounds as topoisomerase II poisons.

212 s used in the repair of DNA damage caused by topoisomerase II poisons.

213 of drugs and environmental toxins are potent topoisomerase II poisons.

214 that promote chromosomal damage also act as topoisomerase II poisons.

215 n the absence of cohesion, but inhibition of topoisomerase II prevents their resolution in anaphase.

216 differences in torsional stress, as shown by topoisomerase II relaxation and activation of different

217 We further show that topoisomerase II relaxation displays a strong preference

218 While PBCV-1 and CVM-1 topoisomerase II relaxed under- and overwound substrates

219 NA meshwork of meiotic chromosome axes, with topoisomerase II required to adjust spatial relationship

220 here is considerable interest in elucidating topoisomerase II roles, particularly as these proteins a

221 , small interfering RNA (siRNA) knockdown of topoisomerase II significantly reduced cccDNA amplificat

222 ino acid identity to the catalytic domain of topoisomerase II, suggesting a partial gene duplication

223 ation as biomarkers of responsiveness to DNA topoisomerase II-targeted therapy.

224 cific inhibitors to overcome the tendency of topoisomerase II-targeting chemotherapeutics to generate

225 e report a new function of the mitochondrial topoisomerase II (TbTOP2mt).

226 te the clinical success of drugs that target topoisomerase II, the development of resistant cancer ce

227 Thus, a topological change on DNA drives topoisomerase II to decatenate molecules during mitosis,

228 rug kills cells by inhibiting the ability of topoisomerase II to ligate nucleic acids that it cleaves

229 BCV-1) and chlorella virus Marburg-1 (CVM-1) topoisomerase II to relax and cleave negatively and posi

230 Thus, etoposide requires the presence of topoisomerase II to show specific sensitization in the a

231 s the scientific background behind targeting topoisomerase II together with a number of other targets

232 of essential chromosome-segregation factors: topoisomerase II(TOP-2), CENP-A(HCP-3), cohesin, and to

233 ble-strand breaks (DSBs) induced by abortive topoisomerase II (TOP2) activity are a potential source

234 e absence of both topoisomerase I (Top1) and topoisomerase II (Top2) activity, processivity was sever

235 hydrolyze 5'-phosphotyrosyl linkage between topoisomerase II (Top2) and DNA raises the question whet

236 one of the major eukaryotic topoisomerases, Topoisomerase II (Top2) and nucleosomes in the budding y

237 y.DNA double-strand breaks (DSBs) induced by topoisomerase II (TOP2) are rejoined by TDP2-dependent n

238 med cells involves thiol modification of DNA topoisomerase II (Top2) based on the following observati

239 ng 5'-tyrosyl DNA adducts formed by abortive topoisomerase II (Top2) cleavage complexes to allow erro

240 our data indicate that disrupting Drosophila topoisomerase II (Top2) gene function with RNAi and chem

241 Topoisomerase II (Top2) is an essential enzyme that deca

242 Topoisomerase II (Top2) is an essential enzyme that reso

243 DNA topoisomerase II (Top2) is an essential nuclear enzyme a

244 For instance, topoisomerase II (Top2) is critically important for reso

245 DNA topoisomerase II (TOP2) is required for the unwinding an

246 Topoisomerase II (Top2) is the primary target for active

247 We show that GCNA and topoisomerase II (TOP2) physically interact in both mice

248 DNA topoisomerase II (TOP2) plays a pivotal role in faithful

249 n as a DUB inhibitor, PR-619 is a potent DNA topoisomerase II (TOP2) poison, inducing both DNA topois

250 specifically repairs DNA damages induced by topoisomerase II (Top2) poisons and causes resistance to

251 Topoisomerase II (TOP2) poisons are effective cytotoxic

252 Topoisomerase II (TOP2) poisons as anticancer drugs work

253 that anthracyclines and mitoxantrone act as topoisomerase II (TOP2) poisons at low concentration but

254 how that the therapeutic cytotoxicity of DNA topoisomerase II (TOP2) poisons can be enhanced through

255 nd immature myeloid cells and transforms the topoisomerase II (TOP2) poisons etoposide and mitoxantro

256 s, in response to etoposide, an inhibitor of topoisomerase II (TOP2) re-ligation activity.

257 Topoisomerase II (TOP2) relieves topological stress in D

258 Topoisomerase II (TOP2) relieves torsional stress by for

259 Topoisomerase II (TOP2) removes torsional stress from DN

260 Here, we report observations linking yeast Topoisomerase II (Top2) to both CEN mechanics and assess

261 ed during replication are decatenated by DNA topoisomerase II (TOP2), and this process is actively mo

262 Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), do

263 The decatenation activity of topoisomerase II (Top2), which is widely conserved withi

264 Here, we investigated the processing of topoisomerase II (Top2)-DNA adducts induced by treatment

265 Topoisomerase II (TOP2)-targeting poisons such as anthra

266 se anthracyclines work in part by inhibiting topoisomerase-II (TOP2) on accessible DNA(3,4), we hypot

267 al targets have been proposed, including DNA topoisomerases II (Top2).

268 repair pathway, whereas another for the DNA topoisomerase II (TOP2A) poison etoposide identified TOP

269 Previous studies have demonstrated that topoisomerase II (TopII)-DNA adducts (TopII-DNA covalent

270 ted by treatment of breast cancer cells with topoisomerase II (Topo II) drugs, whereas paclitaxel (Ta

271 sensitive measurements of the life essential topoisomerase II (Topo II) enzyme activity.

272 zed that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide.

273 prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, respectively.

274 Topoisomerase II (topo II) is a ubiquitous enzyme that i

275 Topoisomerase II (Topo II) is essential for mitosis sinc

276 (AML) inhibit the activity of the mammalian topoisomerase II (topo II) isoforms, topo II alpha and t

277 To allow chromosome segregation, topoisomerase II (topo II) must resolve sister chromatid

278 Topoisomerase II (Topo II) performs topological modifica

279 To investigate the potency of the topoisomerase II (topo II) poisons doxorubicin and etopo

280 Topoisomerase II (Topo II) poisons such as etoposide can

281 , showed a higher potential to interact with topoisomerase II (Topo II) than did the other Ginkgo bil

282 olecular target of resveratrol is eukaryotic topoisomerase II (topo II), an enzyme essential for chro

283 ies, and hypersensitivity to an inhibitor of Topoisomerase II (Topo II), ICRF-193.

284 me segregation failure after inactivation of topoisomerase II (topo II), the enzyme that removes cate

285 ng anaphase also fails after inactivation of topoisomerase II (topo II), the enzyme that removes cate

286 of doxorubicin was not due to inhibition of topoisomerase II (Topo II).

287 Topoisomerase II (Topo-II) is an essential enzyme in the

288 riant CENP-A and the DNA decatenizing enzyme topoisomerase-II (topo-II) as candidate modulators of ch

289 Chemotherapies such as the topoisomerase II (TopoII) inhibitor etoposide effectivel

290 We previously reported a first set of hybrid topoisomerase II (topoII) poisons whose chemical core me

291 roquinazoline derivatives that inhibit human topoisomerase II (topoII), a validated target of antican

292 , chromosomes present high levels of de novo Topoisomerase II (TopoII)-dependent re-entanglements, an

293 Topoisomerase II (TopoII)-targeting agents are commonly

294 Topoisomerase II transcript accumulation was observed du

295 enerated T. brucei lines expressing T. cruzi topoisomerase-II truncated at the carboxyl terminus and

296 bimodal recognition of DNA geometry in which topoisomerase II uses elements in the C-terminal domain

297 nzyme-DNA interface, several quinones poison topoisomerase II via redox-dependent protein adduction.

298 Through immuno-localization of topoisomerase II was observed diffusely throughout the n

299 to an increase in and activation of unbound topoisomerase II, which, in the presence of a topoisomer

300 els of random strand passage, for example by topoisomerase II, would result in entanglements, increas